The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Ruxolitinib and decitabine in patients with post-MPN AML
Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale, study design and results from a Phase I/II study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
